Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy
BRCA1 and BRCA2 germline mutations are associated with a strong risk of breast cancer, which may preclude breast-conserving treatment in carriers. This study examined whether mutation status influenced the rate of breast cancer recurrence following breast-conserving treatment. BRCA1 and BRCA2 genes...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2005-10, Vol.41 (15), p.2304-2311 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2311 |
|---|---|
| container_issue | 15 |
| container_start_page | 2304 |
| container_title | European journal of cancer (1990) |
| container_volume | 41 |
| creator | Kirova, Youlia M. Stoppa-Lyonnet, Dominique Savignoni, Alexia Sigal-Zafrani, Brigitte Fabre, Nicolas Fourquet, Alain |
| description | BRCA1 and
BRCA2 germline mutations are associated with a strong risk of breast cancer, which may preclude breast-conserving treatment in carriers. This study examined whether mutation status influenced the rate of breast cancer recurrence following breast-conserving treatment.
BRCA1 and
BRCA2 genes were screened for germline mutations in 131 patients with a family history of breast and/or ovarian cancer, who had been treated with breast-conserving surgery and radiotherapy. The 131 patients with familial history were matched to 261 patients without, according to age at diagnosis and year of treatment. The follow-up of controls was at least equal to the time-interval between diagnosis and genetic testing in familial cases. Matched cohorts were compared according to rates of breast cancer recurrence as first event and contralateral breast cancer using log-rank tests.
BRCA1/2 mutations were found in 20.6% patients with a family history. Nineteen patients had a
BRCA1 mutation and 8 had a
BRCA2 mutation. Breast cancers in mutation carriers were more often grade III (
p
<
10-4) and oestrogen receptor negative (
p
=
0.005) than tumours in both non-carriers and controls. Median follow-up for all 392 patients was 8.75 years. No significant differences in breast cancer recurrence as first event were seen between
BRCA1/2 tumours and controls (
p
=
0.47), carriers and non-carriers with a family history (
p
=
0.96), or non-carriers and controls (
p
=
0.10). On multivariate analysis, age was the most important factor significantly predicting for breast cancer recurrence. The rate of contralateral breast cancer was significantly increased in all patients with a family history:
BRCA1/2 carriers
versus controls (
p
=
0.0003), non-carriers
versus controls (
p
=
0.0034) and carriers
versus non-carriers (
p
=
0.02). At a 9-year median follow-up, the rate of ipsilateral breast cancer recurrence was not higher in
BRCA1 and
BRCA2 mutation carriers than in non-carriers with a family history or sporadic cases. These results support the hypothesis that breast tumours in
BRCA carriers are more sensitive to radiation. Therefore, breast-conserving treatment can be offered to these patients. However, longer follow-up is needed to ensure that the rate of new primary cancer in the treated breast does not increase in the long-term. |
| doi_str_mv | 10.1016/j.ejca.2005.02.037 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68673544</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804905006027</els_id><sourcerecordid>17422325</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-bfe73aa83213e6fcc71b0e062d85ed53a20a28c08264e5163412a47d68e33c8e3</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EotPCC7BA3sAu4fonjiOxaUcUkCpVqsra8jg3xUMmHuykaN6HB8XpRKrEot34Xvt-59jyIeQdg5IBU5-2JW6dLTlAVQIvQdQvyIrpuilAV_wlWUFTNYUG2ZyQ05S2AFBrCa_JCVNM5p1akb83Pv2ioaObiDaN1NnBYaQR3RQj5p7aoaUuDGO0vR0xr_-hfsh0Hvkw0DHQi5v1OXsQzR2nu2k8zlKuU6Jd6Pvwxw93i02RvRPG-_kkTfEO4-FBHW3rw_gzX7g_vCGvOtsnfLvUM_Lj8svt-ltxdf31-_r8qnCiUWOx6bAW1mrBmUDVOVezDSAo3uoK20pYDpZrB5oriRVTQjJuZd0qjUK4vJyRj0fffQy_J0yj2fnksO_tgGFKRmlVi0rKZ0FWS84FrzLIj6CLIaWIndlHv7PxYBiYOUSzNXOIZg7RADc5xCx6v7hPmx22j5IltQx8WACbnO27mJPw6ZGrmVZaNpn7fOQwf9q9x2iS83Oorc8Bj6YN_ql3_AOS77za</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17422325</pqid></control><display><type>article</type><title>Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kirova, Youlia M. ; Stoppa-Lyonnet, Dominique ; Savignoni, Alexia ; Sigal-Zafrani, Brigitte ; Fabre, Nicolas ; Fourquet, Alain</creator><creatorcontrib>Kirova, Youlia M. ; Stoppa-Lyonnet, Dominique ; Savignoni, Alexia ; Sigal-Zafrani, Brigitte ; Fabre, Nicolas ; Fourquet, Alain ; for the Institut Curie Breast Cancer Study Group ; Institut Curie Breast Cancer Study Group</creatorcontrib><description>BRCA1 and
BRCA2 germline mutations are associated with a strong risk of breast cancer, which may preclude breast-conserving treatment in carriers. This study examined whether mutation status influenced the rate of breast cancer recurrence following breast-conserving treatment.
BRCA1 and
BRCA2 genes were screened for germline mutations in 131 patients with a family history of breast and/or ovarian cancer, who had been treated with breast-conserving surgery and radiotherapy. The 131 patients with familial history were matched to 261 patients without, according to age at diagnosis and year of treatment. The follow-up of controls was at least equal to the time-interval between diagnosis and genetic testing in familial cases. Matched cohorts were compared according to rates of breast cancer recurrence as first event and contralateral breast cancer using log-rank tests.
BRCA1/2 mutations were found in 20.6% patients with a family history. Nineteen patients had a
BRCA1 mutation and 8 had a
BRCA2 mutation. Breast cancers in mutation carriers were more often grade III (
p
<
10-4) and oestrogen receptor negative (
p
=
0.005) than tumours in both non-carriers and controls. Median follow-up for all 392 patients was 8.75 years. No significant differences in breast cancer recurrence as first event were seen between
BRCA1/2 tumours and controls (
p
=
0.47), carriers and non-carriers with a family history (
p
=
0.96), or non-carriers and controls (
p
=
0.10). On multivariate analysis, age was the most important factor significantly predicting for breast cancer recurrence. The rate of contralateral breast cancer was significantly increased in all patients with a family history:
BRCA1/2 carriers
versus controls (
p
=
0.0003), non-carriers
versus controls (
p
=
0.0034) and carriers
versus non-carriers (
p
=
0.02). At a 9-year median follow-up, the rate of ipsilateral breast cancer recurrence was not higher in
BRCA1 and
BRCA2 mutation carriers than in non-carriers with a family history or sporadic cases. These results support the hypothesis that breast tumours in
BRCA carriers are more sensitive to radiation. Therefore, breast-conserving treatment can be offered to these patients. However, longer follow-up is needed to ensure that the rate of new primary cancer in the treated breast does not increase in the long-term.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2005.02.037</identifier><identifier>PMID: 16140006</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Aged ; Biological and medical sciences ; BRCA1/2 mutations ; Breast Neoplasms - genetics ; Breast Neoplasms - radiotherapy ; Breast Neoplasms - surgery ; Breast-conserving treatment ; Epidemiologic Methods ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Germ-Line Mutation - genetics ; Heterozygote ; Humans ; Mastectomy, Segmental ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - genetics ; Pharmacology. Drug treatments ; Polymerase Chain Reaction - methods ; Radiotherapy ; Recurrence ; Tumors</subject><ispartof>European journal of cancer (1990), 2005-10, Vol.41 (15), p.2304-2311</ispartof><rights>2005 Elsevier Ltd</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-bfe73aa83213e6fcc71b0e062d85ed53a20a28c08264e5163412a47d68e33c8e3</citedby><cites>FETCH-LOGICAL-c396t-bfe73aa83213e6fcc71b0e062d85ed53a20a28c08264e5163412a47d68e33c8e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejca.2005.02.037$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17186849$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16140006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kirova, Youlia M.</creatorcontrib><creatorcontrib>Stoppa-Lyonnet, Dominique</creatorcontrib><creatorcontrib>Savignoni, Alexia</creatorcontrib><creatorcontrib>Sigal-Zafrani, Brigitte</creatorcontrib><creatorcontrib>Fabre, Nicolas</creatorcontrib><creatorcontrib>Fourquet, Alain</creatorcontrib><creatorcontrib>for the Institut Curie Breast Cancer Study Group</creatorcontrib><creatorcontrib>Institut Curie Breast Cancer Study Group</creatorcontrib><title>Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>BRCA1 and
BRCA2 germline mutations are associated with a strong risk of breast cancer, which may preclude breast-conserving treatment in carriers. This study examined whether mutation status influenced the rate of breast cancer recurrence following breast-conserving treatment.
BRCA1 and
BRCA2 genes were screened for germline mutations in 131 patients with a family history of breast and/or ovarian cancer, who had been treated with breast-conserving surgery and radiotherapy. The 131 patients with familial history were matched to 261 patients without, according to age at diagnosis and year of treatment. The follow-up of controls was at least equal to the time-interval between diagnosis and genetic testing in familial cases. Matched cohorts were compared according to rates of breast cancer recurrence as first event and contralateral breast cancer using log-rank tests.
BRCA1/2 mutations were found in 20.6% patients with a family history. Nineteen patients had a
BRCA1 mutation and 8 had a
BRCA2 mutation. Breast cancers in mutation carriers were more often grade III (
p
<
10-4) and oestrogen receptor negative (
p
=
0.005) than tumours in both non-carriers and controls. Median follow-up for all 392 patients was 8.75 years. No significant differences in breast cancer recurrence as first event were seen between
BRCA1/2 tumours and controls (
p
=
0.47), carriers and non-carriers with a family history (
p
=
0.96), or non-carriers and controls (
p
=
0.10). On multivariate analysis, age was the most important factor significantly predicting for breast cancer recurrence. The rate of contralateral breast cancer was significantly increased in all patients with a family history:
BRCA1/2 carriers
versus controls (
p
=
0.0003), non-carriers
versus controls (
p
=
0.0034) and carriers
versus non-carriers (
p
=
0.02). At a 9-year median follow-up, the rate of ipsilateral breast cancer recurrence was not higher in
BRCA1 and
BRCA2 mutation carriers than in non-carriers with a family history or sporadic cases. These results support the hypothesis that breast tumours in
BRCA carriers are more sensitive to radiation. Therefore, breast-conserving treatment can be offered to these patients. However, longer follow-up is needed to ensure that the rate of new primary cancer in the treated breast does not increase in the long-term.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>BRCA1/2 mutations</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - radiotherapy</subject><subject>Breast Neoplasms - surgery</subject><subject>Breast-conserving treatment</subject><subject>Epidemiologic Methods</subject><subject>Female</subject><subject>Genes, BRCA1</subject><subject>Genes, BRCA2</subject><subject>Germ-Line Mutation - genetics</subject><subject>Heterozygote</subject><subject>Humans</subject><subject>Mastectomy, Segmental</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymerase Chain Reaction - methods</subject><subject>Radiotherapy</subject><subject>Recurrence</subject><subject>Tumors</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhS0EotPCC7BA3sAu4fonjiOxaUcUkCpVqsra8jg3xUMmHuykaN6HB8XpRKrEot34Xvt-59jyIeQdg5IBU5-2JW6dLTlAVQIvQdQvyIrpuilAV_wlWUFTNYUG2ZyQ05S2AFBrCa_JCVNM5p1akb83Pv2ioaObiDaN1NnBYaQR3RQj5p7aoaUuDGO0vR0xr_-hfsh0Hvkw0DHQi5v1OXsQzR2nu2k8zlKuU6Jd6Pvwxw93i02RvRPG-_kkTfEO4-FBHW3rw_gzX7g_vCGvOtsnfLvUM_Lj8svt-ltxdf31-_r8qnCiUWOx6bAW1mrBmUDVOVezDSAo3uoK20pYDpZrB5oriRVTQjJuZd0qjUK4vJyRj0fffQy_J0yj2fnksO_tgGFKRmlVi0rKZ0FWS84FrzLIj6CLIaWIndlHv7PxYBiYOUSzNXOIZg7RADc5xCx6v7hPmx22j5IltQx8WACbnO27mJPw6ZGrmVZaNpn7fOQwf9q9x2iS83Oorc8Bj6YN_ql3_AOS77za</recordid><startdate>200510</startdate><enddate>200510</enddate><creator>Kirova, Youlia M.</creator><creator>Stoppa-Lyonnet, Dominique</creator><creator>Savignoni, Alexia</creator><creator>Sigal-Zafrani, Brigitte</creator><creator>Fabre, Nicolas</creator><creator>Fourquet, Alain</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>200510</creationdate><title>Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy</title><author>Kirova, Youlia M. ; Stoppa-Lyonnet, Dominique ; Savignoni, Alexia ; Sigal-Zafrani, Brigitte ; Fabre, Nicolas ; Fourquet, Alain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-bfe73aa83213e6fcc71b0e062d85ed53a20a28c08264e5163412a47d68e33c8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>BRCA1/2 mutations</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - radiotherapy</topic><topic>Breast Neoplasms - surgery</topic><topic>Breast-conserving treatment</topic><topic>Epidemiologic Methods</topic><topic>Female</topic><topic>Genes, BRCA1</topic><topic>Genes, BRCA2</topic><topic>Germ-Line Mutation - genetics</topic><topic>Heterozygote</topic><topic>Humans</topic><topic>Mastectomy, Segmental</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymerase Chain Reaction - methods</topic><topic>Radiotherapy</topic><topic>Recurrence</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kirova, Youlia M.</creatorcontrib><creatorcontrib>Stoppa-Lyonnet, Dominique</creatorcontrib><creatorcontrib>Savignoni, Alexia</creatorcontrib><creatorcontrib>Sigal-Zafrani, Brigitte</creatorcontrib><creatorcontrib>Fabre, Nicolas</creatorcontrib><creatorcontrib>Fourquet, Alain</creatorcontrib><creatorcontrib>for the Institut Curie Breast Cancer Study Group</creatorcontrib><creatorcontrib>Institut Curie Breast Cancer Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kirova, Youlia M.</au><au>Stoppa-Lyonnet, Dominique</au><au>Savignoni, Alexia</au><au>Sigal-Zafrani, Brigitte</au><au>Fabre, Nicolas</au><au>Fourquet, Alain</au><aucorp>for the Institut Curie Breast Cancer Study Group</aucorp><aucorp>Institut Curie Breast Cancer Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2005-10</date><risdate>2005</risdate><volume>41</volume><issue>15</issue><spage>2304</spage><epage>2311</epage><pages>2304-2311</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>BRCA1 and
BRCA2 germline mutations are associated with a strong risk of breast cancer, which may preclude breast-conserving treatment in carriers. This study examined whether mutation status influenced the rate of breast cancer recurrence following breast-conserving treatment.
BRCA1 and
BRCA2 genes were screened for germline mutations in 131 patients with a family history of breast and/or ovarian cancer, who had been treated with breast-conserving surgery and radiotherapy. The 131 patients with familial history were matched to 261 patients without, according to age at diagnosis and year of treatment. The follow-up of controls was at least equal to the time-interval between diagnosis and genetic testing in familial cases. Matched cohorts were compared according to rates of breast cancer recurrence as first event and contralateral breast cancer using log-rank tests.
BRCA1/2 mutations were found in 20.6% patients with a family history. Nineteen patients had a
BRCA1 mutation and 8 had a
BRCA2 mutation. Breast cancers in mutation carriers were more often grade III (
p
<
10-4) and oestrogen receptor negative (
p
=
0.005) than tumours in both non-carriers and controls. Median follow-up for all 392 patients was 8.75 years. No significant differences in breast cancer recurrence as first event were seen between
BRCA1/2 tumours and controls (
p
=
0.47), carriers and non-carriers with a family history (
p
=
0.96), or non-carriers and controls (
p
=
0.10). On multivariate analysis, age was the most important factor significantly predicting for breast cancer recurrence. The rate of contralateral breast cancer was significantly increased in all patients with a family history:
BRCA1/2 carriers
versus controls (
p
=
0.0003), non-carriers
versus controls (
p
=
0.0034) and carriers
versus non-carriers (
p
=
0.02). At a 9-year median follow-up, the rate of ipsilateral breast cancer recurrence was not higher in
BRCA1 and
BRCA2 mutation carriers than in non-carriers with a family history or sporadic cases. These results support the hypothesis that breast tumours in
BRCA carriers are more sensitive to radiation. Therefore, breast-conserving treatment can be offered to these patients. However, longer follow-up is needed to ensure that the rate of new primary cancer in the treated breast does not increase in the long-term.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>16140006</pmid><doi>10.1016/j.ejca.2005.02.037</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2005-10, Vol.41 (15), p.2304-2311 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68673544 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Biological and medical sciences BRCA1/2 mutations Breast Neoplasms - genetics Breast Neoplasms - radiotherapy Breast Neoplasms - surgery Breast-conserving treatment Epidemiologic Methods Female Genes, BRCA1 Genes, BRCA2 Germ-Line Mutation - genetics Heterozygote Humans Mastectomy, Segmental Medical sciences Middle Aged Neoplasm Recurrence, Local - genetics Pharmacology. Drug treatments Polymerase Chain Reaction - methods Radiotherapy Recurrence Tumors |
| title | Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T07%3A02%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20of%20breast%20cancer%20recurrence%20and%20contralateral%20breast%20cancer%20in%20relation%20to%20BRCA1%20and%20BRCA2%20mutation%20status%20following%20breast-conserving%20surgery%20and%20radiotherapy&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Kirova,%20Youlia%20M.&rft.aucorp=for%20the%20Institut%20Curie%20Breast%20Cancer%20Study%20Group&rft.date=2005-10&rft.volume=41&rft.issue=15&rft.spage=2304&rft.epage=2311&rft.pages=2304-2311&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2005.02.037&rft_dat=%3Cproquest_cross%3E17422325%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17422325&rft_id=info:pmid/16140006&rft_els_id=S0959804905006027&rfr_iscdi=true |